Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:REPH

Recro Pharma (REPH) Stock Price, News & Analysis

Recro Pharma logo

About Recro Pharma Stock (NASDAQ:REPH)

Key Stats

Today's Range
N/A
50-Day Range
$1.47
$2.11
52-Week Range
N/A
Volume
141,800 shs
Average Volume
126,298 shs
Market Capitalization
$117.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive REPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

REPH Stock News Headlines

Fuji Pharma Co. Ltd.
Here's what Wall Street expects from Recro Pharma's earnings report
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
What Wall Street expects from Recro Pharma's earnings
Mankind Pharma Ltd (MNKI)
See More Headlines

REPH Stock Analysis - Frequently Asked Questions

Recro Pharma, Inc. (NASDAQ:REPH) released its earnings results on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. Recro Pharma had a negative trailing twelve-month return on equity of 56.66% and a negative net margin of 15.15%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Recro Pharma investors own include Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), SCYNEXIS (SCYX), Gilead Sciences (GILD) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
3/01/2022
Today
9/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REPH
CIK
1588972
Employees
185
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.37 million
Net Margins
-15.15%
Pretax Margin
-15.09%
Return on Equity
-56.66%
Return on Assets
-11.14%

Debt

Debt-to-Equity Ratio
2.27
Current Ratio
3.24
Quick Ratio
2.74

Sales & Book Value

Annual Sales
$75.36 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.90 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
56,424,000
Free Float
48,412,000
Market Cap
$117.93 million
Optionable
Optionable
Beta
1.08
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:REPH) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners